Harrow Health Inc. (HROW) is an emerging and dynamic company based in the United States that is heavily invested in the healthcare sector. It operates with a strong commitment towards innovating and driving growth in pharmaceuticals.
Founded in 2011 by Mark Baum as Imprimis Pharmaceuticals, the company started with the aim of improving the affordability and accessibility of the medications the world needs most. In 2018, the company rebranded to Harrow Health and continued to expand its product offerings while staying true to its mission.
Harrow Health Inc. operates with a vision of creating, developing, and rectifying inefficiencies in the healthcare marketplace. It seeks to identify promising pharmaceutical assets and compounds in the market, buying them and formulating strategies for their commercialization and ultimate success.
The company's unique business model is characterized by its vertical integration pattern. It operates on a diversified platform combining pharmaceutical compounding, drug innovation, and vision technologies. With its emphasis on the patient's needs and the delivery of quality healthcare, Harrow has been instrumental in developing more than 100 proprietary formulations for use in various medical disciplines including ophthalmology, urology, and otolaryngology.
Harrow's diverse portfolio not only supports various medical disciplines but also includes Harrow Health's wholly-owned subsidiary, Eton Pharmaceuticals which is focused on developing and commercializing innovative treatments for rare pediatric diseases. Another significant subsidiary is ImprimisRx, which operates a pharmaceutical compounding business from FDA-inspected facilities across the United States, providing accessible and high-quality medications to patients.
Harrow Health Inc. is characterized by its commitment to growth through innovation, its devotion to improving patient experiences and outcomes, and its dedication to addressing underlying market inefficiencies in the healthcare sector. Its strategy and the implementation of that strategy have placed them prominently on the healthcare map and back their potential as a company geared towards making a lasting impact.
As of the current time, its novel business approach, along with a strong pipeline of proprietary formulated medicines and specialized services tailored to individual patient needs, has underlined its strength as a contender in the healthcare industry. The future for Harrow Health Inc. is indeed promising as it constantly strives to bring transformative medications to market. Led by an experienced, focused, and committed leadership team, Harrow Health Inc. is certainly a company to watch in the ever-evolving pharmaceutical sector.